Results 241 to 250 of about 4,430,461 (355)

Cancer therapy‐induced ototoxicity: Current challenges and emerging management strategies

open access: yesAnimal Models and Experimental Medicine, EarlyView.
This review comprehensively examines the key risk factors for cancer therapy‐induced ototoxicity, including cumulative drug dose, genetic susceptibility, and combined treatment regimens. It highlights current challenges in ototoxicity monitoring, such as insufficient timeliness and limited clinical adoption, and advocates for standardized auditory ...
Yuqi Huang   +4 more
wiley   +1 more source

Delirium education priorities for healthcare professional students: a modified Delphi study. [PDF]

open access: yesBMC Med Educ
Anderson T   +19 more
europepmc   +1 more source

Human Leukocyte Elastase Triggered Nanoparticles for Targeted Antimicrobial Delivery and Oral Microbial Modulation

open access: yesAdvanced NanoBiomed Research, EarlyView.
This study explores enzyme‐responsive nanoparticles for targeted antimicrobial release in inflamed oral environments. Nanoparticles formed by complexing peptides and chlorhexidine respond to human leukocyte elastase and release chlorhexidine selectively. P7 (ECAAPVCE)‐based formulations show optimal properties and stability, with antimicrobial activity
Mohammed A. Hadis   +9 more
wiley   +1 more source

Embedding Chemistry and Pharmacy Into Sustainability

open access: yesAngewandte Chemie International Edition, EarlyView.
Chemistry and pharmacy provide products and processes that are indispensable for our high living standard. To understand their relationship with sustainability is important to allow them to contribute to sustainability in a sustainable manner. An integrated overview of green, circular, and sustainable chemistry and pharmacy is given and how they have t
Klaus Kümmerer
wiley   +1 more source

Single‐Cell Level Characterization of B Cell Depletion and Repopulation Following Rituximab in Systemic Lupus Erythematosus

open access: yesArthritis &Rheumatology, EarlyView.
Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang   +9 more
wiley   +1 more source

Interprofessional collaboration to improve professional practice and healthcare outcomes.

open access: yesCochrane Database of Systematic Reviews, 2017
S. Reeves   +4 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy